Navigation Links
BioSpecifics Technologies Corp. to Present at UBS Global Life Sciences Conference
Date:9/14/2010

LYNBROOK, N.Y., Sept. 14 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that BioSpecifics' President, Tom Wegman, will present at the upcoming UBS Global Life Sciences Conference on Monday, September 20, 2010, at 7:30am ET at the Grand Hyatt New York in New York City.

A live webcast of the presentation can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at http://www.biospecifics.com, or you may use the link: http://cc.talkpoint.com/ubsx001/092110a_lv/?entity=130_6627G0J.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for eleven clinical indications, three of which include: Dupuytren's contracture, Peyronie's disease, and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium markets XIAFLEX in the U.S. for the treatment of Dupuytren's contracture. Pfizer, Inc. is responsible for marketing XIAFLEX in Europe. More information about BioSpecifics may be found on its website at http://www.biospecifics.com.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results
2. BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease
3. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
4. BioSpecifics Technologies Corp. to Present at Piper Jaffray 20th Annual Health Care Conference
5. BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market
6. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results
7. BioSpecifics Technologies Corp. Announces FDA Acceptance of Biologics License Application With Priority Review for XIAFLEX(TM) for the Treatment of Dupuytrens Disease
8. BioSpecifics Technologies Corp. Reports First Quarter 2009 Financial Results
9. BioSpecifics Technologies Corp. Added to Russell 3000 and Russell 2000 Indexes
10. BioSpecifics Technologies Corp. to Present at CapStone Investments Third Annual Small-Cap Investor Conference
11. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2009 Financial Results on August 12, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... Ca (PRWEB) , ... January 11, 2017 , ... ... U.S. each year and costing healthcare systems more than $23.7 billion, healthcare ... controlling costs. , Among the most common sepsis-causing pathogens are bacteria and ...
(Date:1/11/2017)... (PRWEB) , ... January 11, 2017 , ... ... company developing an innovative cellular response analysis platform to measure the proteomic function ... Phase I Small Business Innovation Research (SBIR) grant from the National Institute on ...
(Date:1/11/2017)... Rockwall Texas (PRWEB) , ... January 11, 2017 , ... ... Clinics. No Drugs, No Shots and No Surgery for positive back pain relief for ... 150,000 documented positive results worldwide and could be life changing for millions suffering from ...
(Date:1/11/2017)... 11, 2017 AnaptysBio, Inc., a clinical-stage ... on unmet medical needs in inflammation, today announced ... chief financial officer.  Mr. Piscitelli will play a ... as overseeing the company,s accounting and SEC reporting ... welcome Dominic to the senior management team at ...
Breaking Biology Technology:
(Date:1/12/2017)...  Trovagene, Inc. (NASDAQ: TROV ), a ... that it has signed agreements with seven strategic partners ... Middle East for commercialization of the ... wave of international distribution agreements for Trovagene,s CLIA based ... The initial partners will introduce Trovagene,s liquid biopsy ...
(Date:1/11/2017)... NEW BRUNSWICK, N.J. , Jan. 11, 2017  Michael Johnson, ... from Foundation Venture Capital Group, Inc., has been named to the ... Johnson, 27,  was one of 600 people in 20 fields ... only four percent of the 15,000 applicants were selected. ... He is currently a PhD ...
(Date:1/4/2017)...  For the thousands of attendees at this year,s International Consumer Electronics ... and biometric measurement devices and services, will be featuring its new line ... A&D Medical,s special CES Exhibit Suite , the new upper arm ... company,s WellnessConnected product platform.  ... ...
Breaking Biology News(10 mins):